GUBRA Share Price Performance
DKK 448.00
-162.00 (-26.56%)
10.8% undervalued intrinsic discount
DKK 502.50
Fair Value
Price DKK 448.00
AnalystConsensusTarget DKK 502.50
Fair ValueDKK 502.50
Share Pricen/a
Gubra A/S Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
GUBRA Community Narratives
AN
Fair Value DKK 502.5 10.8% undervalued intrinsic discount
Specialized CRO Models Will Expand Drug Discovery Amid Uncertainty
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Specialized CRO Models Will Expand Drug Discovery Amid Uncertainty
Key Takeaways Expansion of proprietary peptide pipeline and major partnerships diversify revenue streams and enhance earnings resilience beyond core CRO services. Investments in advanced preclinical platforms and global reach position Gubra to capture a larger, higher-margin market as outsourcing in biotech grows.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
DKK 502.5
10.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-54% p.a.
Profit Margin
73.41%
Future PE
49.78x
Share price in 2028
DKK 569.94
Snowflake Analysis
Gubra A/S Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 27, 2026
- 106.86
- 96.36%
- 66.22%
- 0%
About GUBRA
- Founded
- 2008
- Employees
- 275
- CEO
- WebsiteView website
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, pharmacokinetics, and 2D and 3D histology with artificial intelligence pathology. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Hemab ApS to treat bleeding disorders; and Amylyx Pharmaceuticals, Inc. to develop a novel long-acting GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is based in Horsholm, Denmark.
